This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krige, D. Articles by Drummond, A. H. Search for Related Content PubMed PubMed Citation Articles by Krige, D. Articles by Drummond, A. H.

CHR-2797: An Antiproliferative Aminopeptidase Inhibitor that Leads to Amino Acid Deprivation in Human Leukemic Cells

¹ Chroma Therapeutics Ltd., Abingdon, United Kingdom; ² British Biotech Pharmaceuticals Ltd., Oxford, United Kingdom; and ³ The Institute of Cancer Research, Sutton, United Kingdom

Requests for reprints: David Krige, Chroma Therapeutics Ltd., 93 Milton Park, Abingdon, Oxon, OX14 4RY, United Kingdom. Phone: 44-1235-829120; Fax: 44-1235-829125; E-mail: dkrige{at}chromatherapeutics.com.

Key Words: amino acid deprivation • aminopeptidase • CHR-2797

CHR-2797 is a novel metalloenzyme inhibitor that is converted into a pharmacologically active acid product (CHR-79888) inside cells. CHR-79888 is a potent inhibitor of a number of intracellular aminopeptidases, including leucine aminopeptidase. CHR-2797 exerts antiproliferative effects against a range of tumor cell lines in vitro and in vivo and shows selectivity for transformed over nontransformed cells. Its antiproliferative effects are at least 300 times more potent than the prototypical aminopeptidase inhibitor, bestatin. However, the mechanism by which inhibition of these enzymes leads to proliferative changes is not understood. Gene expression microarrays were used to profile changes in mRNA expression levels in the human promyelocytic leukemia cell line HL-60 treated with CHR-2797. This analysis showed that CHR-2797 treatment induced a transcriptional response indicative of amino acid depletion, the amino acid deprivation response, which involves up-regulation of amino acid synthetic genes, transporters, and tRNA synthetases. These changes were confirmed in other leukemic cell lines sensitive to the antiproliferative effects of CHR-2797. Furthermore, CHR-2797 treatment inhibited phosphorylation of mTOR substrates and reduced protein synthesis in HL-60 cells, both also indicative of amino acid depletion. Treatment with CHR-2797 led to an increase in the concentration of intracellular small peptides, the substrates of aminopeptidases. It is suggested that aminopeptidase inhibitors, such as CHR-2797 and bestatin, deplete sensitive tumor cells of amino acids by blocking protein recycling, and this generates an antiproliferative effect. CHR-2797 is orally bioavailable and currently undergoing phase II clinical investigation in the treatment of myeloid leukemia. [Cancer Res 2008;68(16):6669–79]

This article has been cited by other articles:

				A. H.M. Reid, A. Protheroe, G. Attard, N. Hayward, L. Vidal, J. Spicer, H. M. Shaw, E. A. Bone, J. Carter, L. Hooftman, et al. A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors Clin. Cancer Res., August 1, 2009; 15(15): 4978 - 4985. [Abstract] [Full Text] [PDF]

				H. E. Moore, E. L. Davenport, E. M. Smith, S. Muralikrishnan, A. S. Dunlop, B. A. Walker, D. Krige, A. H. Drummond, L. Hooftman, G. J. Morgan, et al. Aminopeptidase inhibition as a targeted treatment strategy in myeloma Mol. Cancer Ther., April 1, 2009; 8(4): 762 - 770. [Abstract] [Full Text] [PDF]